|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Enhancing PSMA-uptake with androgen deprivation therapy - a new way to detect prostate cancer metastases?
|
30901173 |
2019 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Adding SN biopsy in patients with a negative PSMA PET/CT increases the combined sensitivity to 100% for detecting nodal metastases at ePLND.
|
31562222 |
2019 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
On the other hand Ga-68 PSMA-11 PET/CT had significant successful results for detection of LN metastases when compared with mp-MRI.
|
31012125 |
2019 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The highest significant positive correlation between LN size and SUV was in patients with pelvic and abdominal LN metastases without bone involvement according to the gallium-68 PSMA PET/computed tomography images in our study.
|
31107410 |
2019 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
To evaluate the diagnostic performance of [<sup>68</sup>Ga]Ga-PSMA<sup>HBED-CC</sup> conjugate 11 positron emission tomography (PSMA-PET) in the early detection of metastases in patients with biochemical recurrence (BCR) after radical prostatectomy (RP) for clinically non-metastatic prostate cancer, to compare it to CT/MRI alone and to assess its impact on further therapeutic decisions.
|
29075832 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
<sup>68</sup>Ga-PSMA is the diagnostic positron-emitting theranostic pair with the beta emitter Lutetium-177 PSMA (<sup>177</sup>Lu-PSMA) and alpha-emitter Actinium-225 PSMA (<sup>225</sup>Ac-PSMA) which can both be used to treat PSMA-avid metastases of prostate cancer in the molecular tumor-targeted approach of theranostic nuclear oncology.
|
29439481 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Six patients with prostate cancer (PCa) with suspicion of LNM on preoperative PSMA PET/CT underwent <sup>111</sup>In-PSMA-617-guided lymphadenectomy (LA; four salvage LA and two primary LA).
|
30062606 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
<sup>68</sup>Ga-PSMA PET/CT is superior to and can potentially replace bone scan in the evaluation for skeletal metastases in the clinical and trial setting because of its ability to detect lytic and bone marrow metastases.
|
30120038 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
68Ga-PSMA avid lesions were most commonly detected in the prostate (n = 193, 43%), loco-regional spread (n = 51, 11%), abdomino-pelvic nodes (n = 129, 29%) and distant metastases (n = 158, 36%), including bone metastases (n = 11, 25%), distant lymphadenopathy (n = 29, 7%) and other organs (n = 18, 4%).
|
30382889 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
PSMA PET/CT scans were performed and patients with PSA persistence (109 patients) or evidence of distant metastases (5 patients) were excluded from this analysis.
|
30002108 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data suggest that <sup>68</sup>Ga-PSMA-11 PET should be combined with <sup>18</sup>F-NaF PET in PC patients with skeletal metastases for restaging prior to initiation or modification of therapy.
|
29766246 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Prostate-specific membrane antigen (PSMA) is specific for prostate cancer cells; nevertheless when finding uptake in abnormal locations for prostate cancer metastases, it is important to consider other hypothesis, including second cancers.
|
30358621 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
<sup>68</sup>Ga-PSMA-11 is currently the most popular prostate-specific membrane antigen (PSMA) radioligand used in the clinic to detect prostate cancer and metastases.
|
29920108 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
PSMA uptake was detected in prostate bed in nine patients, in six patients in distant metastases (bone, lung and liver) and in nine patients in lymph nodes.
|
29777523 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In 5 of 6 patients, there was concordance in the number of metastases identified with <sup>68</sup>Ga-HBED-PSMA-11 and <sup>68</sup>Ga-THP-PSMA.
|
28986512 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
One hundred twenty-nine patients underwent PSMA PET/CT due to biochemical persistence (52%) or recurrence (48%) after radical prostatectomy without evidence of distant metastases (February 2014-May 2017) and received PSMA PET/CT-based radiotherapy.
|
29499730 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Modern imaging methods that use PET-CT with tumour-specific radiotracers (choline or prostate-specific membrane antigen ligand), and increasingly whole-body MRI with diffusion-weighted imaging, allow earlier and more precise identification of metastases.
|
30303127 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The mean SUV<sub>max</sub> of PSMA-negative metastases was 1.0±0.5 in 2D ROI and 1.0±0.4 in 3D ROI, and significantly lower than that of the pulmonary opacities (p<0.001).
|
29769114 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Clinical parameters and established risk stratification systems for PCa can predict Ga-68-PSMA PET-positive metastases in treatment-naïve patients.
|
29978529 |
2018 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
[68Ga]PSMA-11, which is the most frequently applied tracer, has shown to detect lymph node metastases, local recurrences, distant metastases and intraprostatic foci with high sensitivity, even at relatively low PSA levels.
|
29869483 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Prostate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases.
|
29873291 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
68Ga-labeled prostate-specific membrane antigen-targeted ligand positron emission tomography/computed tomography (PSMA-PET/CT) revealed tracer uptake in inguinal, pelvic, and retroperitoneal metastases.
|
28063603 |
2017 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of PSMA in ovarian cancer metastases was similar among different metastatic foci of the same tumor.
|
26862945 |
2017 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
68Ga-PSMA Uptake in Combined Hepatocellular Cholangiocarcinoma With Skeletal Metastases.
|
28806238 |
2017 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
All primary tumours showed PSMA expression on immunohistochemistry (5-90% expression), as well as all available specimens of local recurrence and distant metastases.
|
28593386 |
2017 |